This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years.

The successful closure of this inspection will allow the company to register and market its products in Australia and other rest of world markets which recognize Australian GMP.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets

The company's consolidated net profit jumped 38.8% to Rs 1.18 crore as compared with Rs 0.85 crore in Q1 FY23. Net sales fell 0.4% year on year to Rs 260.17 crore in Q1 FY24.